Microstructure Imaging, Inc. appears in FDA records as the applicant on a single 510(k) premarket notification, K261305, for a device named MICSI-PET. The filing was received on April 20, 2026, and decided on September 11, 2026, with decision code SESE, meaning substantially equivalent, under product code KPS and 21 CFR 892.1200. The company's website describes a second product, MICSI-RMT, as FDA 510(k) cleared for MRI image enhancement under K241121, a filing that is not among the numbered sources here. [1][3][7]
The K261305 filing and its scope
K261305 is a Traditional 510(k) reviewed by the Radiology panel, with a Summary as the statement or summary type and no third-party review. The record lists the applicant as Microstructure Imaging, Inc. at 370 Jay St., Floor 7, Brooklyn, NY 11201, with Gregory Lemberskiy as contact. The device is classified as Class 2 under 21 CFR 892.1200, product code KPS, in the openFDA device name category for computed emission tomography systems. [1][7]
The FDA decision letter describes MICSI-PET as Software as a Medical Device intended to enhance positron emission tomography brain images, and states that the agency reviewed the section 510(k) premarket notification of intent to market the device. A third-party device record summarizes the indications for use as image processing software for image enhancement in PET and notes attributes of Software as a Medical Device and Real-World Evidence. [5][7]
Predicate comparison and review conclusion
The filing materials compare MICSI-PET with the predicate’s intended use environment, user and output. They describe non-clinical and rater study testing in support of a substantial-equivalence conclusion. These are characterizations recorded in the FDA filing materials, rather than independent clinical results. [5][7]
A device record describes the processing path as image data moving to a picture archiving and communication system, then to a DICOM router and processor. That description concerns software workflow placement rather than clinical performance, and no outcome measures are documented in the numbered sources. [7]
MICSI-RMT and the company's stated positioning
The company's website states that MICSI-RMT (K241121) is FDA 510(k) cleared for MRI image enhancement and that MICSI-PET had a completed FDA 510(k) submission awaiting clearance at the time of that page's text. The same page describes the company's aim to make MRI and PET imaging more accessible, more cost effective and more diagnostically powerful, and to create a non-invasive diagnostic tool for assessing the cellular microenvironment. These are company statements attributed to their publisher. [3][4]
The site also lists brain and prostate areas alongside denoising content and shows example image comparisons labeled with MP-PCA processing. Those materials are company-published illustrations; the numbered sources do not document clinical validation, customer deployments or commercial availability for either product. [3][4]
What the record does and does not establish
As of the snapshot date, the supplied collection contains one linked 510(k) record, K261305, with one SESE decision; the record sample contains that same single entry. These counts describe the supplied filings only and are not measures of total portfolio, sales or safety performance. The K241121 clearance is described on the company's site but is not among the numbered sources. [1][3]
Ownership, parent entities, headquarters and commercial status are not established by the numbered sources. The Brooklyn address appears as the applicant address in the FDA filing and is not treated here as a verified headquarters. One company domain page contains unrelated third-party gambling text, so its product statements are used only where consistent with other company pages. [1][3][6]

